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Acute vascular insufficiency of intestines (AVI) is a rare cause
of severe abdominal pain contributing to 0.09% to 2% of
admissions in surgical emergency. Despite its rarity, it needs
early recognition because of its high mortality of 40% to 80%
requiring timely diagnosis and prompt intervention. Occlusion
of mesenteric vessels by arterial embolism (50%) or thrombo-
sis (15% to 25%) and venous thrombosis (5%) are the predo-
minant underlying causes. However, AVI may be nonocclusive
in 20% to 30% of the patients.1,2 Normally intestinal ischemia
is prevented by its high perfusion through celiac mesenteric
artery, superior mesenteric artery/inferior mesenteric artery,
and a parallel system of venous drainage.3 Therefore, bowel
ischemia can occur only when blood supply is markedly
reduced to 75% or more leading to a continuum of intestinal
necrosis, perforation, infarction, or gangrene stimulating a
severe inflammatory response that may be fatal.4 Recently,
activation of Janus kinase/transducer signaling pathway is pro-
posed as an underlying mechanism for mesenteric ischemia.5
Bowel ischemia is of interest to the clinical hematologist
because of its association with thromboembolism. Hematolo-
gists are frequently consulted for anticoagulating patients having
AVI with or without concomitant bleeding risks. It is important
for the hematologists to know the pathophysiology of bowel
ischemia, rationale of anticoagulation, preferred anticoagulants,
and the selection of patients for thrombophilia screening. This
study was conducted to evaluate the clinicopathological spec-
trum and outcome of thrombosis in acute mesenteric ischemia at
Aga Khan University, Karachi, Pakistan, for 5 years from Jan-
uary 2011 to October 2015 (ERC approval: 3872-Pat-ERC-15).
International Classification of Diseases (ICD) classification 9
was used to identify admitted patients with AVI. Only patients
with confirmed radiological or surgical diagnoses were included.
Information was collected from medical chart and cross checked
through computerized data system of the hospital. Demo-
graphics, risk factors, clinical features, laboratory/radiological
investigations, duration of hospitalization, medical or surgical
interventions, and mortality were studied. Complete blood
count, coagulation profile, liver function test, and serum
amylase, lipase, and lactate were analyzed. Thrombophilia
screening and serum homocysteine were done at the doctor’s
discretion and therefore were analyzed where available. Data
were collected, managed, edited, entered, and analyzed by SPSS
version 22 and checked for normality. Median and interquartile
range (IQR) for descriptive and Mann-Whitney for comparing
groups were used for skewed data. Binary logistic regression
was applied to determine the risk factors for mortality. Threshold
of significance was a P value <.05.
ICD coding identified 117 patients for AVI. After removing
duplication (n ¼ 25) and patients with exclusive portal vein
thrombosis (n ¼ 3) or omental infarcts (n ¼ 3), 86 individuals
were evaluable for bowel ischemia. Mean age of the patients
was 49.8 + 18 years and male to female ratio was 1.6:1.
Overall severe abdominal pain was the commonest presenting
complain seen in 80% of patients. Other symptoms in the order
of frequency were vomiting (41%), nausea (34%), constipation
(23%), abdominal distention (21%), fever (19%), diarrhea
(15%), and hematochezia (9%). Computed tomography scan
was done in 80% of the patients for confirming diagnosis, and
positive findings for bowel ischemia (pneumatosis intestinalis,
gas in portal vein, or bowel dilation) were observed in only half
of them. Superior mesenteric vein thrombosis (MVT) with
concomitant involvement of portal vein, splenic vein, and
inferior vena cava was observed in 26, 11, and 2 patients,
respectively. Table 1 summarizes the demographics and main
clinical findings in the patients with (n ¼ 51) and without
thrombosis (n ¼ 35). Main causes identified were thrombosis
of superior mesenteric vein (45%), nonocclusive mesenteric
ischemia or NOMI (41%), and mesenteric artery occlusion
1 Department of Pathology and Laboratory Medicine, Aga Khan University,
Karachi, Pakistan
2 Aga Khan Medical College, Karachi, Pakistan
Corresponding Author:
Bushra Moiz, Department of Pathology and Laboratory Medicine, The Aga
Khan University Hospital, Karachi, Pakistan.
Email: bushra.moiz@aku.edu
Clinical and Applied
Thrombosis/Hemostasis
Volume 26: 1-4
ª The Author(s) 2020
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/1076029620932999
journals.sagepub.com/home/cat
Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons
Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use,
reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access
pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
(14%). Sepsis was the most common underlying pathology in
nonocclusive AVI (54%), while malignancy (n ¼ 14 or 25%)
and thrombophilia (n ¼ 7 or 16%) were the predominant risk
factors for MVT (Figure 1). Predisposing cancers include pan-
creatic (n ¼ 6), hepatocellular carcinoma (n ¼ 2), gastric (n ¼
1), colon (n¼ 1), Ewing’s sarcoma (n¼ 1), polycythemia rubra
vera (n ¼ 1), and essential thrombocythemia (n ¼ 1). Causes
identified for mesenteric arterial occlusion (MAO) were ather-
osclerosis (n ¼ 5) and atrial fibrillation (n ¼ 3) (Figure 1).
Anemia was a significant finding observed in 47% of females
and 61% of males. Leukocytosis and thrombocytopenia were
seen in 48 (56%) and 22 (26%) patients, respectively. Elevated
serum amylase, lipase, and amylase were seen in 16%, 14%,
and 41% of patients, respectively. Lower platelet counts and
higher lactate levels were observed in patients with NOMI
compared to patients with thrombotic disease (P ¼ .018,
.004, respectively). Only 12 and 17 patients were tested for
serum homocysteine and thrombophilia screening. Hyperho-
mocysteinemia and thrombophilia were observed in 66% and
47% of tested patients. Overall, 85% patients were anticoagu-
lated (30 with NOMI and 43 with MAO/MVT). Eight patients
having thrombosis were not anticoagulated either due to imme-
diate death (n ¼ 4) or high risk of bleeding (n ¼ 4). Surgical
patients were anticoagulated with unfractionated heparin (n ¼
37) and later switched to either low-molecular-weight heparin
(LMWH) (n ¼ 13) or warfarin (n ¼ 2). Surgery was performed
in 45 (52%) of 86 patients and bowel resection was performed
in 33 patients (75%). Surgical findings were significant for
gangrenous bowel in 24% of patients, while perforations, infarc-
tion, ischemia, and necrosis were observed in another 29% of the
patients. Nonsalvageable bowel was observed in 10% of patients
with a 100% mortality. Surgical intervention (P < .001) with
subsequent bowel resection (P < .001) was more frequent in
NOMI than those without it (Table 1). Patients’ stay in hospital
ranged from 1 to 65 days with a median (IQR 3-1) of 6 days (13-
2). Those who died had a shorter median hospital stay compared
to the patients who were discharged alive (2.5 vs 7.5 days;
P ¼ .001). Overall, 35% of the patients died in hospital and the
mortality was higher in patients with NOMI than those without it
(49% vs 25%; P ¼ .032). Regression analysis (Table 2) showed
female gender, comorbidities, NOMI, abdominal pain, short hos-
pital stay, prolonged prothrombin time (PT)/activated partial
thromboplastin time, and high serum lactate as statistically sig-
nificant predictors of mortality. However, only PT and serum
lactate maintained this significance in multiple regression.
This study depicted few key differences with earlier reports
such as a high prevalence of mesenteric venous thrombosis and
in a relatively younger age-group. In contrast, earlier reports
from West have showed MAO as the most important cause of
bowel ischemia.6 This was frequently reported in elderly pop-
ulation because of significant prevalence of cardiovascular
morbidity in the aging population.7 Our findings reconciled
with the report from India where 48% of 117 patients with AVI
had MVT at a median age of 53 years.8
The study showed no statistically significant differences in
demographics and clinical presentations between the patients
Table 1. Summary of Clinical Details and Diagnostics in Patients With Acute Bowel Ischemia (n ¼ 86).a
Reference range With thrombosis Without thrombosis P All patients
n (%) – 51 (59.3) 35 (40.7) – 86 (100)
Gender M/F – 37/14 17/18 – 54/32
Age in years, mean + 1SD – 49.2 + 18.0 50.7 + 18.1 .707 49.8 + 18.0
Comorbidities, n (%) – 17 (33.3) 17 (48.6) .165 34 (39.5)
Abdominal pain, n (%) – 43 (84.3) 26 (74.3) .274 69 (80.2)
Fever, n (%) – 9 (17.6) 7 (20) .786 16 (18.6)
Hematochezia, n (%) – 6 (11.8) 2 (5.7) .320 8 (9.3)
Hemoglobin, g/dL 13.7-16.3 M
11.1-14.5 F
11.2 (12.2-9.4) 12.3 (13.5-10.3) .702 11.3 (13.2-10.0)
Total white cell count, 109/L 4-10 13 (18.3-8.5) 9.8 (15.0-5.3) .147 11.6 (17.2-11.6)
Platelet count, 109/L 150-400 233 (330-172) 172 (247-139) .018b 208 (289-141)
Prothrombin time, seconds 9-11 12.5 (14.5-11.9) 12.6 (14.2-11.3) .620 12.6 (14.3-11.8)
Total bilirubin, mg/dL 0.1-1.2 1.3 (2.7-0.5) 0.7 (1.6-0.4) .363 1.0 (2.4-0.5)
Amylase, IU/L 28-100 46.5 (124.7-26) 77 (121-30) .563 53 (121.5-27)
Lactate, mmol//L 0.5-2.2 2 (4.8-1.2) 4.7 (8.1-2.6) .004b 3 (6.5-1.4)
Lipase, U/L 13-60 36 (140-27) 32.5 (115.5-24.2) .565 34.5 (128-25.5)
CT scan done, n (%) – 51 (100) 23 (65.7) 74 (80.0)
CT positive for AMI, n (%) – 23 (45) 11 (31.4) .202 34 (39.5)
Anticoagulation, n (%) – 43 (84) 30 (85.7) .861 66 (76.7)
Surgical intervention, n (%) – 16 (31.4) 29 (82.9) <.001b 45(52.3)
Surgical resection, n (%) – 12 (23.5) 21 (60) <.001b 33 (38.4)
Hospital stay, days – 7 (14-3) 5 (12-2) .395 6 (13-2)
Mortality, n (%) – 13 (25.5) 17 (48.6) .032b 30 (35)
Abbreviations: AMI, acute myocardial infarction; CT, computed tomography; F, female; IQR, interquartile range; M, male.
aLaboratory values are median (IQR 3-1).
bP < .05 is statistically significant; all continuous variables are median (IQR 3-1).
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with or without thrombosis. Patients with thrombotic disease
presented with higher platelet count (P ¼ .018), lower lactate
(P¼ .004), required less surgical intervention and bowel resec-
tion (P < 0.001), and had a lower morality (P ¼ .032) when
compared to nonthrombotic patients. Malignancy and throm-
bophilia were the predominant underlying pathology for MVT
as reported earlier,9 and 50% of these patients having throm-
bophilia had previous history of recurrent spontaneous venous
thromboembolism (VTE). Management of MVT is challen-
ging. It requires multidisciplinary approach involving hematol-
ogists having special interest in thrombosis. The principles and
practices of treating other VTE are applicable to some extent to
MVT as well. Hematologists are frequently consulted for
thrombophilia screening. Available evidence does not favor
such screening in unselected patients. In this study, only 20%
of the patients were screened for inherited thrombophilia
based on the institutional criteria of screening young patients
(<40 years of age) with no other identifiable cause. Moreover,
British Committee of Standards in Hematology guidelines do
not recommend thrombophilia testing after initial episode of
intra-abdominal thrombosis because of its indeterminate
value in defining thrombotic recurrence and the duration of
anticoagulation.10 However, testing for JAK 2 mutation
may be considered in the diagnosis of unprovoked mesenteric
thrombosis.11
Systemic anticoagulation is recommended in all patients
with AVI to prevent thrombus development or propagation,
vessel blockage, and bowel infarction provided there is a low
risk of hemorrhage. Moreover, anticoagulation is typically con-
tinued following surgical exploration to avoid new thrombus
formation.1 Success rate of anticoagulation is reported high at
95% in venous mesenteric ischemia with a lower recurrence
rate and mortality (13%) in heparinized patients.12 Stable and
symptom-free patients may be switched to warfarin for 3 to
6 months if risk factors are reversible. In contrast, anticoagula-
tion should be continued indefinitely for unknown or persistent
risk factors.13 It is also suggested to anticoagulate an incidental
MVT particularly if the patient has un underlying thrombophi-
lia or previous history of VTE,14 and the duration of anticoa-
gulation may be similar to symptomatic MVT.13 During this
study, 85% of patients with AVI were heparinized initially and
continued with either LMWH or vitamin K agonist. None of the
patients received direct oral anticoagulants (DOACs). Direct
oral anticoagulants are an attractive option for treating bowel
ischemia because of fixed dosing, no laboratory monitoring,
and absent drug, disease, and food interactions. Few have
reported successful treatment with DOACs in non-neoplastic
portal vein thrombosis,15,16 but more evidence is needed prior
to their usage because of significant gastrointestinal bleeding
risk (with at least some of the DOACs).
This study showed that patients with mesenteric thrombosis
had better prognosis than nonthrombotic bowel ischemia.
Prompt anticoagulation and surgical intervention (as per need)
were instrumental in successful management.
Figure 1. Risk factors for bowel ischemia in 86 patients according to
underlying etiology: nonocclusive mesenteric ischemia (NOMI),
mesenteric vein thrombosis (MVT), and mesenteric arterial occlusion
(MAO).
Table 2. Multivariate Analysis for All-Cause Mortality in Patients Having Ischemic Bowel Disease (n ¼ 86).
Study parameters
Univariate logistics Multiple regression
Sig. OR (95% CI; lower to upper) Sig. OR (95% CI; lower to upper)
Female gender 0.026 2.857 (1.136 to 7.186) – –
Coronary disease 0.025 6.75 (1.269 to 35.892) – –
Diabetes mellitus 0.036 3.709 (1.091 to 12.615) – –
Nonocclusive mesenteric ischemia 0.029 2.761 (1.106 to 6.888) – –
Chronic liver disease 0.010 16.739 (1.948 to 143.857) – –
Abdominal pain 0.001 11.657 (3.635 to 37.386) – –
Hospital stay 0.009 1.11 (1.026 to 1.2) – –
Prothrombin time 0.033 0.848 (0.729 to 0.987) 0.007 1.146 (1.037 to 1.267)
Activated partial thromboplastin time 0.030 0.947 (0.902 to 0.995) – –
Serum lactate levels 0.004 0.759 (0.627 to 0.918) 0.016 0.762 (0.61 to 0.95)
Abbreviations: OR, odd ratio; Sig, significance level.
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